The Swiss are on the offensive against cancer. This is industry focus.

Hi everyone, welcome to the health care edition of Industry Focus I'm your

host Christine Harajus and we've got Todd Campbell on the show via Skype our

regular health care contributor Todd how's it going?

It's good how are you?

Pretty good it's Veterans Day here in the US so a special

shout out to all of our veterans that are listening today.

Really interesting news out of Exelixis this week and we'll also later in the show be talking

about Colorado for a reason other than marijuana for once.

But first, what does Switzerland have to do with anything?

Well, one piece of Exelixis's recent news was the approval of its

new drug Kotelic in the U.S. So this drug was approved as a combination therapy with the

Swiss company Roche's

Zelberath to treat a specific variation of advanced melanoma.

Now, Zelberath has been on the market already for five years.

Sales are kind of slowing down a little bit, so I'm sure Roach investors are quite

pleased and cheering for this approval, which didn't really come as much of a surprise as

the combination was already approved in Switzerland and a European Union advisory

panel also recommended its approval in the EU so we can probably expect one

there sometime in the future as well. So let's dig into this new drug combo a little bit.

Todd, can you walk us through some of the highlights

of its clinical performance?

...